News
![Agilent Announces Cash Dividend of 18 Cents Per Share](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on July 22, 2020, to all shareholders of record as of the close of
![Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida
Leading health and well-being company Humana Inc. (NYSE: HUM) and Healthmap Solutions, Inc., a specialty population health management company with kidney health expertise, today announced a
![Veeva Enables CROs to Build Studies Faster with Vault EDC](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Enables CROs to Build Studies Faster with Vault EDC
Veeva Systems (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC. As part of the CRO partner program, CROs are trained and receive best
![Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
Veeva Systems (NYSE: VEEV) today announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials. Vault Site Connect automates the flow of
![Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials
Veeva Systems (NYSE: VEEV) today announced MyVeeva, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to
![Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for
![Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!
Gilead Sciences (WKN: 885823), CytoDyn (WKN: A0YHA5) und Evotec (WKN: 566480) – die Aktien der drei Pharmaunternehmen sind in diesem Jahr – trotz oder gerade wegen Corona – vergleichsweise gut
![Pfizer Prices $4,000,000,000 Debt Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Prices $4,000,000,000 Debt Offering
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:
$750,000,000 aggregate principal amount of 0.800% notes due 2025
$1,000,000,000
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research
Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in
![Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer
![Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary
![Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three
![Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it is ranked #1 in Florida and Texas in the 2020 J.D. Power ranking of Commercial member health plans. Humana has
![Humana’s Annual Report on Employee Well-Being Illustrates the Company’s Culture and Highlights Resiliency](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Humana’s Annual Report on Employee Well-Being Illustrates the Company’s Culture and Highlights Resiliency
Humana Inc. (NYSE: HUM) has released its latest annual report on employee well-being, which continues to show that passion for whole-person well-being, both inside and outside the workplace, can
![Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day on Monday, September 14, 2020 at 9:00 a.m. EDT. Pfizer postponed its Investor Day, originally scheduled
![New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the RBC Capital Markets
![Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral
Agilent Technologies Inc. (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge
![DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes
DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 (the “notes”) in a private
![Humana Specialty Pharmacy Wins National Award for Third Consecutive Year](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Humana Specialty Pharmacy Wins National Award for Third Consecutive Year
Humana Specialty Pharmacy has received the Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the third year in a row. The award, presented by Zitter Health Insights, a division
![Humana Announces Additional Bold Goal Communities in Cincinnati and Detroit](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Humana Announces Additional Bold Goal Communities in Cincinnati and Detroit
Humana Inc. (NYSE: HUM) announced today that Cincinnati, Ohio and Detroit, Michigan are the latest additions to its Bold Goal communities. The Bold Goal is Humana’s population health strategy to
![DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes
DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior
![Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020
DexCom, Inc. (NASDAQ:DXCM) today announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. (the “Company”)